Hepatotoxicity of antidepressants

Area of Science:

• Hepatology
• Clinical Pharmacology
• Psychopharmacology

Background:

• Abnormal liver function tests (LFTs) in patients on psychopharmacological agents pose a clinical dilemma.
• Experimental data suggest hepatotoxic potential, but clinical incidence data in humans are scarce.
• Differentiating drug-induced liver injury from other causes is complex.

Purpose of the Study:

• To review the clinical implications of abnormal liver function tests in patients treated with psychopharmacological agents.
• To discuss the challenges in diagnosing drug-induced liver injury (DILI) from these medications.
• To highlight the spectrum of hepatic reactions associated with psychotropic drugs.

Main Methods:

• Review of existing literature on drug-induced liver injury (DILI) from psychopharmacological agents.
• Discussion of the classification of hepatic drug reactions (predictable vs. unpredictable).
• Analysis of clinical presentation and diagnostic challenges.

Main Results:

• Most psychotropic drug-related hepatic reactions are unpredictable and dose-independent.
• The spectrum of liver injury ranges from minor biochemical abnormalities to severe hepatitis and cholestasis.
• Fatal outcomes and chronic liver disease have been reported.

Conclusions:

• Clinicians face challenges in managing patients with abnormal LFTs on psychotropic medications.
• Unpredictable hepatic reactions are a significant concern with psychopharmacological agents.
• Careful evaluation is needed to attribute liver dysfunction to drug therapy.